The Food and Drug Administration (FDA) informed that Granulex Aerosol Spray (trypsin, balsam peru, castor oil; Mylan) has been discontinued due to market conditions.
Telemedicine monitoring is not associated with any significant difference in amputation or healing, but may be linked to increased mortality for patients with diabetic foot ulcers.
A new "smart bandage" has been developed that can detect early tissue damage from pressure ulcers before they are visible to the human eye.
Hospital-acquired conditions (HACs) experienced a 17% decline from 2010-2013 and a 9% reduction from 2012-2013, according to figures released by the Centers for Medicare & Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS).
Patient-specific orthoses manufactured on the basis of foot shape and barefoot plantar pressure are better compared to those manufactured only on the basis of foot shape and clinical insight.
ConvaTec has launched Aquacel Ag Foam dressing, the latest addition to the Aquacel family of wound management products.
SilvrSTAT Antibacterial Wound Dressing Gel , from ABL Medical, manages 1st and 2nd-degree burns, stasis ulcers, pressure ulcers, diabetic ulcers, lacerations, abrasions, skin tears, surgical incision sites, device insertion site wounds, and graft and donor sites. SilvrSTAT is available in 1oz or 3oz tubes.
Derma Sciences, Inc. announced the U.S. launch and first commercial sales of Medihoney HCS (hydrogel colloidal sheet) for the treatment of first- and second-degree burns, in addition to various chronic and acute wounds.
A spray-based therapy containing growth-arrested allogeneic neonatal keratinocytes and fibroblasts, HP802-247, is associated with a reduction in the wound area of chronic venous leg ulcers.
For patients with diabetic foot ulcers (DFUs), long-term limb salvage is favorable; however, long-term survival remains poor, particularly for those with peripheral artery disease (PAD) or chronic renal insufficiency.
For patients with diabetes, increased poly(ADP-ribose) (PAR) immunoreactivity, reduced abundance of type 1 procollagen, and impaired skin structure correlate with foot complications.
Cardium Therapeutics announced the launch of Excellagen (bovine Type I collagen gel, 2.6%), a syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers, and other dermal wounds.
Chronic leg ulcers (CLUs) that don't heal after three months of appropriate treatment have an overall skin cancer frequency of 10.4%.
Quinnova has made available its Atrapro brand with two products, Atrapro Antipruritic Hydrogel and Atrapro Dermal Spray with Preservatives.
Hi-Tech Pharmacal and its subsidiary ECR Pharmaceuticals announced the launch of Hylase Wound Gel for the management and treatment of leg ulcers, pressure ulcers, diabetic ulcers, and exuding wounds prone to bleeding.
Derma Sciences announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers.
CardioVascular BioTherapeutics (CVBT) announced that it has submitted an application to the FDA to obtain "fast track" designation for CVBT-141B for the treatment of ischemic diabetic wounds.